~統合再編から世界に向けて~

福島県立医科大学 消化管外科学講座

業績

ホーム > 業績 > 業績集 消化管外科学講座 平成29年(2017年)

業績集 消化管外科学講座 平成29年(2017年)

(1) 論文

①原著(筆頭著者のイニシアル順)
1. Ando J*, Saito M*, Imai J, Ito E, Yanagisawa, Honma R, Saito K*, Tachibana K, Momma T*, Ohki S*, Ohtake T, Watanabe S, Waguri S, Kono K*,Takenoshita S. TBX19 is overexpressed in colorectal cancer and associated with lymph node metastasis. Fukushima J Med Sci. 63(3): 141-151, 2017.
2. George J, Saito M*, Tsuta K, Iwakawa R, Shiraishi K, Scheel AH, Uchida S, Watanabe SI, Nishikawa R, Noguchi M, Peifer M, Jang SJ, Petersen I, Buttner R, Harris CC, Yokota J, Thomas RK, Kohno T. (co-first author) Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer. Clin Cancer Res. 23(5):1220-1226, 2017.
3. Gonda K*, Shibata M*, Ohtake T, Matsumoto Y, Tachibana K, Abe N, Ohto H, Sakurai K, Takenoshita S. Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer. Oncol Lett. 14(2):1766-1774, 2017.
4. Gonda K, Shibata M, Sato Y, Washio M, Takeshita H, Shigeta H, Ogura M, Oka S, Sakuramoto S. Elevated neutrophil to lumphocyte ratio is associated with nutritional impairment, immune suppression, resistance to S-1 plus cisplatin, and poor prognosis in patients with stage IV gastric cancer. Mol Clin Oncol. 7(6): 1073-1078, 2017.
5. Goto A, Tanaka M, Yoshida M, Umakoshi M, Nanjo H, Shiraishi K, Saito M*, Kohno T, Kuriyama S, Konno H, Imai K, Saito H, Minamiya Y, Maeda D. The low expression of miR-451 predicts a worse prognosis in non-small cell lung cancer cases. PLoS One. 12(7):e0181270, 2017.
6. Hayase S*, Kumamoto K*, Saito K*, Kofunato Y, Sato Y*, Okayama H*, Miyamoto K*, Ohki S*, Takenoshita S. L?type amino acid transporter 1 expression is upregulated and associated with cellular proliferation in colorectal cancer. Oncol Lett. 14(6): 7410-7416, 2017.
7. Hayashi H, Kohno T, Ueno H, Hiraoka N, Kondo S, Saito M*, Ichikawa H, Kato M, Shibata T, Morizane C, Sakamoto T, Shimada K, Komatsu Y, Sakamoto N, Okusaka T. The number of mutations among KRAS, CDKN2A, TP53, and SMAD4 as detected using targeted deep sequencing is a useful prognostic biomarker for pancreatic cancer. Pancreas 46(3):335-340, 2017.
8. Kasai N, Sasakawa A, Hosomi K, Poh TW, Chua BL, Yong WP, So J, Chan SL, Soong R, Kono K*, Ishii T, Yamano K. Anti-tumor efficacy evaluation of a novel monoclonal antibody targeting neutral amino acid transporter ASCT2 using patient-derived xenograft mouse models of gastric cancer. Am J Transl Res. 9(7):3399-3410, 2017.
9. Kogashiwa Y, Yasuda M, Sakurai H, Nakahira M, Sano Y, Gonda K*, Ikeda T, Inoue H, Kuba K, Oba S, Ishikawa J, Enoki Y, Matsumura S, Minami K, Ebihara Y, Sugasawa M. PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma. Anticancer Res. 37(3):1417-1424, 2017.
10. Kumamoto K, Endo S, Isohata N, Nirei A*, Nemoto D, Utano K, Saito T, Togashi K. Pseudocirrhosis caused by regorafenib in an advanced rectal cancer patient with multiple liver metastases. Mol Clin Oncol. 6(1):63-66, 2017.
11. Kunisaki C, Miyata H, Konno H, Saze Z*, Hirahara N, Kikuchi H, Wakabayashi G, Gotoh M, Mori M. Modeling preoperative risk factors for potentially lethal morbidities using a nationwide Japanese web-based database of patients undergoing distal gastrectomy for gastric cancer. Gastric Cancer. 20(3):496-507, 2017.
12. Minamikawa K, Shibata M*, Gonda K*, Ujiie D*, Ashizawa M*, Nakajima T*, Okayama H*, Sakamoto W*, Saito M*, Momma T*, Mimura K* , Ohki S*, Shimura T, Ohto H, Takenoshita S, Kono K*. IL-17 and VEGF are significantly associated with disease progression involving systemic inflammation in patients with gastric and colorectal cancers. Ann. Cancer Res. Ther. 25(2):67-76, 2017.
13. Mimura K*, Kua LF, Shimasaki N, Shiraishi K, Nakajima S, Siang LK, Shabbir A, So J, Yong WP, Kono K*. Upregulation of thioredoxin-1 in activated human NK cells confers increased tolerance to oxidative stress. Cancer Immunol Immunother. 66(5):605-613, 2017.
14. Mimura K*, Teh JL, Okayama H*, Shiraishi K, Kua LF, Koh V, Smoot DT, Ashktorab H, Oike T, Suzuki Y, Fazreen Z, Asuncion BR, Shabbir A, Yong WP, So J, Soong R, Kono K*. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci. 2018 Jan;109(1):43-53. doi: 10.1111/cas.13424. Epub 2017 Nov 18.
15. Momma T*, Okayama H*, Saitou M*, Sugeno H*, Yoshimoto N*, Takebayashi Y, Ohki S*, Takenoshita S. Expression of circadian clock genes in human colorectal adenoma and carcinoma. Oncol Lett. 14(5):5319-5325, 2017.
16. Ohkouchi C, Kumamoto K, Saito M*, Ishigame T, Suzuki SI, Takenoshita S, Harris CC. ING2, a tumor associated gene, enhances PAI1 and HSPA1A expression with HDAC1 and mSin3A through the PHD domain and C terminal. Mol Med Rep. 16(5):7367-7374, 2017.
17. Onozawa H*, Saito M*, Saito K*, Kanke Y*, Watanabe Y*, Hayase S*, Sakamoto W*, Ishigame T, Momma T*, Ohki S*, Takenoshita S. Annexin A1 is involved in resistance to 5-FU in colon cancer cells. Oncology Rep. 37(1):235-240, 2017.
18. Saito M*, Fujiwara Y, Asao T, Honda T, Shimada Y, Kanai Y, Tsuta K, Kono K*, Watanabe S, Ohe Y, Kohno T. The genomic and epigenomic landscape in thymic carcinoma. Carcinogenesis, 38(11):1084-1091, 2017.
19. Saito M*, Okayama H*, Saito K*, Ando J, Ohki S*, Ishii Y, Takenoshita S. CDX2 is involved in microRNA-related inflammatory carcinogenesis in gastric cancer. Oncol Lett. 14(5):6184-6190, 2017.
20. Sato H, Niimi A, Yasuhara T, Permata TBM, Hagiwara Y, Isono M, Nuryadi E, Sekine R, Oike T, Kakoti S, Yoshimoto Y, Held KD, Suzuki Y, Kono K*, Miyagawa K, Nakano T, Shibata A. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun. 8(1):1751, 2017
21. Sato Y, Gonda K*, Harada M, Tanisaka Y, Arai S, Mashimo Y, Iwano H, Sato H, Ryozawa S, Takahashi T, Sakuramoto S, Shibata M*. Increased neutrophil-to-lymphocyte ratio is a novel marker for nutrition, inflammation and chemotherapy outcome in patients with locally advanced and metastatic esophageal squamous cell carcinoma. Biomed Rep. 7(1):79-84, 2017.
22. Shimura T, Shibata M*, Gonda K*, Kofunato Y, Okada R, Ishigame T, Kimura T, Kenjo A, Marubashi S, Kono K*, Takenoshita S. Clinical Significance of Soluble Intercellular Adhesion Molecule-1 and Interleukin-6 in Patients with Extrahepatic Cholangiocarcinoma. J Invest Surg. 19:1-8. 2017.
23. Shimura T, Shibata M*, Gonda K*, Kofunato Y, Okada R, Ishigame T, Kimura T, Kenjo A, Kono K*, Marubashi S. Significance of Circulating Galectin-3 in Patients with Pancreatobiliary Cancer. Anticancer Res. 37(9):4979-4986, 2017.
24. Tachibana K, Saito M*, Imai J, Ito E, Yanagisawa, Honma R, Saito K, Ando J, Momma T*, Ohki S*, Ohtake T, Watanabe S, Waguri S and Takenoshita S. Clinicopathological examination on DPEP1 expression in colorectal cancer. Biomed Rep. 6(4):423-428, 2017.
25. Tachibana K, Shibata M, Gonda K, Matsumoto Y, Nakajima T, Abe N, Ohtake T, Shimura T, Ohto H, Kono K and Takenoshita S. IL-17 and vascular endothelial growth factor (VEGF) are increased and correlated to systemic inflammation, immune suppression and malnutrition in patients with breast cancer. European J of Inflammation, 20: 1-10, 2017
26. Tada T*, Honma R, Imai JI, Saze Z*, Kogure M, Marubashi S, Tasaki K, Unakami M, Ezaki J, Tamura H, Nishikawa A, Hashimoto Y, Waguri S, Watanabe S, Gotoh M. A novel gene expression scoring system for accurate diagnosis of basaloid squamous cell carcinoma of the esophagus. Int J Oncol. 51(3):877-886, 2017.
27. Zhu L, Rossi M, Cui Y, Lee RJ, Sakamoto W*, Perry NA, Urs NM, Caron MG, Gurevich VV, Godlewski G, Kunos G, Chen M, Chen W, Wess J. Hepatic β-arrestin 2 is essential for maintaining euglycemia. J Clin Invest. 127(8):2941-2945, 2017.
28. Zhu L, Almaca J, Dadi PK, Hong H, Sakamoto W*, Rossi M, Lee RJ, Vierra NC, Lu H, Cui Y, McMillin SM, Perry NA, Gurevich VV, Lee A, Kuo B, Leapman RD, Matschinsky FM, Doliba NM, Urs NM, Caron MG, Jacobson DA, Caicedo A, Wess J. β-arrestin-2 is an essential regulator of pancreatic β-cell function under physiological and pathophysiological conditions. Nat Commun. 8:14295, 2017.
1. 芦澤舞*, 岡山洋和*, Aung Kyi Thar Min*, 野田勝, 青砥慶太*, 中島隆宏*, 石亀輝英, 三村耕作*, 河野浩二*. ミスマッチ修復機構欠損を有する大腸癌におけるmicroRNAによるPD-L1制御機構. 癌と化学療法. 44(10):889-891, 2017.
2. 大木進司*, 加瀬晃志*, 千田峻*, 早瀬傑*, 藤田正太郎*, 門馬智之*, 高和正, 河野 浩二*, 大竹 徹, 竹之下 誠一. 80歳以上の高齢者大腸癌におけるリスク評価と予後の解析. 癌と化学療法. 43(12):1532-1534, 2016.
3. 志村龍男, 柴田昌彦*, 小船戸康英, 石亀輝英, 岡田良, 木村隆, 見城明, 丸橋繁, 大木進司*, 河野浩二*, 竹之下誠一. 肝胆膵癌における血中galectin-3の意義. 日本臨床外科学会雑誌 78巻4号, 633-637, 2017.
②総説等
1. Kono K*, Yong WP, Okayama H*, Shabbir A, Momma T*, Ohki S*, Takenoshita S, So J. Intraperitoneal chemotherapy for gastric cancer with peritoneal disease: experience from Singapore and Japan. Gastric Cancer. 20(Suppl 1):122-127, 2017.
1. 河野浩二*. 胃癌 化学療法. 日本外科学会雑誌. 118巻3号, 351-353, 2017.
2. 柴田昌彦、河野浩二 癌免疫カンファレンスルーム、連載の開始にあたって、消化器外科40(10): 1474-1476,2017
3. 柴田昌彦 癌免疫カンファレンスルーム、癌患者で起きている生体の変化、消化器外科40(11): 1575-1580,2017
4. 三村耕作*、河野浩二*. がんワクチンと免疫チェックポイント阻害剤. 癌と化学療法. 44(9):733-736, 2017.
5. 三村耕作*、中山裕子、中澤匡男、河野浩二*. 腫瘍微小環境の解析から診た抗PD-1/抗PD-L1抗体の適応. 癌と化学療法. 44(11):981-983, 2017.
③症例報告
1. Abe T, Nirei A*, Suzuki N, Todate Y, Azami A, Waragai M, Sato A, Takano Y, Nishino N, Sakuma H, Teranishi Y. Neuroendocrine tumor of the extrahepatic bile duct: A case report. Int J Surg Case Rep. 40:6-9, 2017.
2. Aoto K*, Shimura T, Kofunato Y, Okada R, Yashima R, Kiko Y, Takenoshita S. Acinar Cell Cystadenocarcinoma of the Pancreas. Case Rep Gastroenterol. 11(2):504-510, 2017.
1. 権田憲士*, 立谷陽介, 畠山優一, 柴田昌彦*, 河野浩二*, 六角裕一. 化学療法によりpCR が得られた直腸癌の2 症例. 癌と化学療法. 44(10):944-946, 2017.
2. 権田憲士*, 柴田昌彦*, 安田政実, 立谷陽介, 畠山優一, 河野浩二*, 六角裕一. 長期生存を認めた原発不明癌の3 症例. 癌と化学療法. 44(10):950-952, 2017.
3. 早瀬 傑*, 藤田正太郎*, 石井芳正, 竹之下誠一. 脾原発性悪性リンパ腫の2 治療例. 福島医学会雑誌. 67(2):75-80, 2017.
4. 藤田正太郎*, 大木進司*, 加瀬晃志*, 山内直人*, 千田峻*, 早瀬傑*, 坂本渉*, 門馬智之*, 高和正, 大竹 徹, 河野 浩二*, 竹之下 誠一. 腹腔鏡下幽門側胃切除術後のポートサイト再発を来した高齢者胃癌の1 例. 癌と化学療法. 43(12):1502-1504, 2016.
5. 松井田 元*, 佐瀬 善一郎*, 大須賀 文彦, 遠藤 久仁*, 多田 武志*, 後藤 満一. 腹腔鏡下に切除し得た隆起型蛋白漏出性胃癌の1例. 福島医学雑誌. 67巻2号,81-88, 2017.
6. 渡部 晶之, 佐瀬 善一郎*, 多田 武志*, 花山 寛之*, 佐藤 哲, 遠藤 久仁*, 木村 隆, 大須賀 文彦, 見城 明, 鈴木 剛, 後藤 満一. 外傷性肝外門脈損傷に対して,大伏在静脈グラフトによる門脈再建により救命しえた1例. 日本消化器外科学会雑誌. 50巻3号, 254-261, 2017.
7. 金田 晃尚*, 佐瀬 善一郎*, 多田 武志*, 花山 寛之*, 遠藤 久仁*, 後藤 満一. 食道GISTを併発したc-KIT陽性食道原発悪性黒色腫の1例. 日本臨床外科学会雑誌. 78巻9号 2027-2033, 2017.

(2) 著書・訳書

1. Shibata M, Gonda K, Takenoshita S. Chapter 14, Systemic Inflammation causing multiple clinical symptoms in gastrointestinal cancer. In Gastrointestinal Cancers vol.2 (Kumar AK and Prasad S ed) pp311-323, Nova Science Publishers, New York 2017
1. 大木進司*、佐瀬善一郎*、早瀬 傑*、花山寛之*、多田武志*、河野浩二*. 食道癌切除後胃管再建不能例における有茎空腸再建術. 手術. 71(13): 1789-1792, 2017
2. 齋藤元伸*, 河野隆志. 遺伝子異常に基づく肺腺がんのprecision medicine. 血液内科. 74(1):109-115, 2017.
3. 多田武志*, 佐瀬善一郎*, 花山寛之*, 丸橋繁, 河野浩二*, 後藤満一. 縦隔内限局型特発性食道破裂に対する経腹的胃底部縫着術. 手術. 71巻7号, 1077-1081, 2017.
4. 岡山洋和*、河野浩二*、竹之下誠一(翻訳).  デヴィータがんの分子生物学 第2版 第19章. メディカルサイエンスインターナショナル:2017/6/2

(3) 知的財産権

1. 岡山洋和*、野田勝、河野浩二*. 出願番号:特願2017-170157. 発明の名称:大腸がんの予後バイオマーカー. 2017/09

お問い合わせcontact

ご相談・ご質問などお気軽にお寄せください

公立大学法人福島県立医科大学 消化管外科学講座
〒960-1295 福島県福島市光が丘1
TEL 024-547-1259